Improved replicon cellular activity of non-nucleoside allosteric inhibitors of HCV NS5B polymerase: From benzimidazole to indole scaffolds
- 1 October 2006
- journal article
- research article
- Published by Elsevier BV in Bioorganic & Medicinal Chemistry Letters
- Vol. 16 (19), 4987-4993
- https://doi.org/10.1016/j.bmcl.2006.07.074
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- The face of future hepatitis C antiviral drug development: Recent biological and virologic advances and their translation to drug development and clinical practiceJournal of Hepatology, 2005
- Global epidemiology of hepatitis C virus infectionThe Lancet Infectious Diseases, 2005
- The therapeutic potential of NS3 protease inhibitors in HCV infectionExpert Opinion on Investigational Drugs, 2005
- Complete Replication of Hepatitis C Virus in Cell CultureScience, 2005
- Production of infectious hepatitis C virus in tissue culture from a cloned viral genomeNature Medicine, 2005
- Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patientsGastroenterology, 2004
- Specific inhibitors of HCV polymerase identified using an NS5B with lower affinity for template/primer substrateNucleic Acids Research, 2004
- Non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase: discovery and preliminary SAR of benzimidazole derivativesBioorganic & Medicinal Chemistry Letters, 2003
- Hepatitis C Virus-Encoded Enzymatic Activities and Conserved RNA Elements in the 3′ Nontranslated Region Are Essential for Virus Replication In VivoJournal of Virology, 2000
- Replication of Subgenomic Hepatitis C Virus RNAs in a Hepatoma Cell LineScience, 1999